来源: Pharmaceutical Technology
The deal will enhance Kyowa Kirin’s focus on addressing the unmet medical needs of individuals with genetic and other severe diseases. Credit: Mongkolchon Akesin/Shutterstock.com. 来源: Pharmaceutical Technology
Kyowa Kirin, a Japan-based global speciality pharmaceutical company, has announced the successful completion of its acquisition of Orchard Therapeutics, a developer of hematopoietic stem cell gene therapies, for an equity value of $477.6m (Y70.47bn). The integration of Orchard into Kyowa Kirin’s operations will enhance the company’s focus on addressing the unmet medical needs of individuals with genetic and other severe diseases. The acquisition will enrich Kyowa Kirin’s portfolio, supporting the development of therapeutic candidates and facilitating the ongoing and future launches of Libmeldy in early-onset MLD. Orchard co-founder and CEO Bobby Gaspar will join Kyowa Kirin’s senior research and development leadership team, reporting to president and CEO Masashi Miyamoto.
Orchard’s employees will continue their work from the company’s existing locations in London, UK, and Boston, US.
Miyamoto said: “We are truly excited about the acquisition of Orchard Therapeutics, a leading provider of HSC gene therapy. “This platform offers significant potential to deliver more innovative treatments and breakthrough therapies and aligns with our purpose to deliver life-changing value for people living with rare and complex diseases.
“Going forward, our companies will build on the extensive experience of Orchard’s gene therapy platform and apply it to under-served indications and diseases where we believe it to be scientifically and clinically differentiated.”
Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.
Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.
Free WhitepaperCell and gene therapies: Pipe dream to pipeline
The cell and gene industry is gaining momentum, with a new wave of therapies promising to transform the way doctors treat, and even cure, disease. In this report, Cytiva and GlobalData have collaborated to explore the rise of the cell and gene therapy industries, the current state of the market, present and future opportunities for advancement, and the challenges that lie ahead. 来源: Pharmaceutical Technology
By downloading this case study, you acknowledge that GlobalData may share your information with Cytiva Thematic and that your personal data will be used as described in their Privacy Policy